Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
Verrica Pharmaceuticals (Nasdaq: VRCA) has scheduled its Q4 and full-year 2024 financial results conference call and webcast for March 11, 2025, at 4:30 p.m. ET. The dermatology therapeutics company will present financial performance data and provide a corporate update during the event.
Participants can join via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) using conference ID: VERRICA. The webcast will be accessible through the company's investor relations website section, with a replay available for 90 days post-event.
Verrica Pharmaceuticals (Nasdaq: VRCA) ha programmato la sua conferenza telefonica e webcast sui risultati finanziari del quarto trimestre e dell'intero anno 2024 per l'11 marzo 2025, alle 16:30 ET. L'azienda specializzata in terapie dermatologiche presenterà i dati sulle performance finanziarie e fornirà un aggiornamento aziendale durante l'evento.
I partecipanti possono unirsi tramite telefono componendo 1-800-445-7795 (nazionale) o 1-785-424-1699 (internazionale) utilizzando l'ID conferenza: VERRICA. Il webcast sarà accessibile attraverso la sezione delle relazioni con gli investitori del sito web dell'azienda, con una registrazione disponibile per 90 giorni dopo l'evento.
Verrica Pharmaceuticals (Nasdaq: VRCA) ha programado su conferencia telefónica y webcast sobre los resultados financieros del cuarto trimestre y del año completo 2024 para el 11 de marzo de 2025, a las 4:30 p.m. ET. La empresa de terapias dermatológicas presentará datos sobre su rendimiento financiero y proporcionará una actualización corporativa durante el evento.
Los participantes pueden unirse por teléfono marcando 1-800-445-7795 (nacional) o 1-785-424-1699 (internacional) utilizando el ID de conferencia: VERRICA. El webcast estará disponible a través de la sección de relaciones con inversores del sitio web de la compañía, con una repetición disponible durante 90 días después del evento.
베리카 제약 (Nasdaq: VRCA)는 2024년 4분기 및 연간 재무 결과에 대한 전화 회의 및 웹캐스트를 2025년 3월 11일 오후 4시 30분 ET에 예정했습니다. 피부과 치료 전문 기업은 행사 중 재무 성과 데이터를 발표하고 회사 업데이트를 제공할 것입니다.
참가자는 전화로 1-800-445-7795 (국내) 또는 1-785-424-1699 (국제)로 전화하여 회의 ID: VERRICA를 사용하여 참여할 수 있습니다. 웹캐스트는 회사의 투자자 관계 웹사이트 섹션을 통해 접근 가능하며, 이벤트 후 90일 동안 다시 시청할 수 있습니다.
Verrica Pharmaceuticals (Nasdaq: VRCA) a programmé sa conférence téléphonique et son webcast sur les résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 11 mars 2025 à 16h30 ET. L'entreprise spécialisée dans les thérapies dermatologiques présentera des données de performance financière et fournira une mise à jour de l'entreprise lors de l'événement.
Les participants peuvent rejoindre par téléphone en composant 1-800-445-7795 (national) ou 1-785-424-1699 (international) en utilisant l'ID de conférence : VERRICA. Le webcast sera accessible via la section des relations avec les investisseurs du site Web de l'entreprise, avec une rediffusion disponible pendant 90 jours après l'événement.
Verrica Pharmaceuticals (Nasdaq: VRCA) hat seine Telefonkonferenz und Webcast zu den finanziellen Ergebnissen des vierten Quartals und des gesamten Jahres 2024 für den 11. März 2025 um 16:30 Uhr ET angesetzt. Das Unternehmen für dermatologische Therapien wird während der Veranstaltung Finanzdaten präsentieren und ein Unternehmensupdate geben.
Teilnehmer können sich telefonisch unter 1-800-445-7795 (national) oder 1-785-424-1699 (international) mit der Konferenz-ID: VERRICA einwählen. Der Webcast wird über den Bereich für Investor Relations der Unternehmenswebsite zugänglich sein, mit einer Wiederholung, die 90 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update.
Individuals may participate in the live call via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.
A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts, one of the largest remaining unmet needs in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com
FAQ
When will Verrica Pharmaceuticals (VRCA) release its Q4 and full-year 2024 earnings?
How can investors access Verrica Pharmaceuticals' (VRCA) Q4 2024 earnings call?
How long will VRCA's Q4 2024 earnings webcast replay be available?
What topics will be covered in Verrica Pharmaceuticals' (VRCA) upcoming earnings call?
